Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:41:25.339Z.
Calculation as of: 2026-10-06T13:41:25.339Z.
Quote observation: 2026-10-06T13:36:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9f471510e2ba483dadfaa738129fdacbeb72ec081face8194c47abf0e776528
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$6.52M
Price/OCF Ratio
N/A
TTM Avg
1251.33
3Y Avg
3596.77
5Y Avg
3596.77
Market Cap
$6.85M
Price/OCF Ratio
N/A
TTM Avg
2077.04
3Y Avg
2435.48
5Y Avg
5326.60
Market Cap
$7.09M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $7.03M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.65M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.80M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.78M | N/A | 5.48 | 12.65 | 12.65 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.52M | N/A | 1251.33 | 3596.77 | 3596.77 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | N/A | 2077.04 | 2435.48 | 5326.60 |
| Biomerica, Inc. (BMRA)vs › | $6.42M | N/A | 119.62 | 119.62 | 119.62 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.09M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.25M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.23M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
